Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study (Q41607636)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 July 2015

Language	Label	Description	Also known as
English	Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study	scientific article published on 6 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Sebastian Grosicki

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Krzysztof Warzocha

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Mieczyslaw Komarnicki

15

object named as

Mieczyslaw Komarnicki

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Wieslaw Jedrzejczak

10

object named as

Wieslaw W Jedrzejczak

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Anna Dmoszyńska

7

object named as

Anna Dmoszynska

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Andrzej Hellmann

5

object named as

Andrzej Hellmann

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Aleksander Skotnicki

4

object named as

Aleksander Skotnicki

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Agnieszka Wierzbowska

13

object named as

Agnieszka Wierzbowska

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Jerzy Hołowiecki

2

object named as

Jerzy Holowiecki

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Sebastian Giebel

16

object named as

Sebastian Giebel

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Janusz Kłoczko

9

object named as

Janusz Kloczko

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Kazimierz Kuliczkowski

3

object named as

Kazimierz Kuliczkowski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Slawomira Kyrcz-Krzemien

6

object named as

Slawomira Kyrcz-Krzemien

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Barbara Zdziarska

12

object named as

Barbara Zdziarska

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Kazimierz Sułek

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Agnieszka Pluta

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

6 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

90

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

904-909

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26149802%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Prognostic factors in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Clinical importance of cytogenetics in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Reduced mortality after allogeneic hematopoietic-cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24113

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41607636&oldid=1925045359"